BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:[IEDC] German-based Life Sciences Company Evonik Invests $220M
  in Tippecanoe County Expansion
X-WR-TIMEZONE:Indiana (East)
BEGIN:VEVENT
DTSTAMP:20261013T123652Z
UID:tag:localist.com\,2008:EventInstance_40129181890199
DTSTART;VALUE=DATE:20220602
DESCRIPTION:New facility in the US will be second company site to produce l
 ipids for mRNA-based therapies globally \n\nLAFAYETTE\, Ind. (June 2\, 202
 2) – Evonik\, a global provider of drug delivery technologies\, announce
 d plans to expand its production facility in Lafayette\, creating more tha
 n 80 highly skilled\, high-wage jobs by the end of 2025. With the expansio
 n\, the complex will be one of the largest sites for active pharmaceutical
  ingredients and Evonik's second-largest site in the U.S. employing 650 pe
 ople. \n\n“Indiana is increasingly a leader in medical innovation due to
  the clustering of quality companies like Evonik that bring high wages and
  future-focused industry to our state\," said Indiana Secretary of Commerc
 e Brad Chambers.  \n\nHeadquartered in Essen\, Germany\, Evonik plans to i
 nvest $220 million to expand its production facility at 1650 Lilly Road in
  Lafayette. The expansion will allow the rapid and flexible production of 
 a variety of lipids that may serve future applications of mRNA technology 
 in infectious disease control\, cancer immunotherapy\, protein replacement
  and gene therapy. The additional facility space also ensures a rapid and 
 extensive supply of lipids to fuel the continuing battle against COVID-19.
 \n\nThe company received up to $150 million in funding for this project fr
 om the Biomedical Advanced Research and Development Authority (BARDA)\, a 
 component of the Office of the Assistant Secretary for Preparedness and Re
 sponse in the U.S. Department of Health and Human Services. BARDA promotes
  the advanced development of medical countermeasures to respond to 21st ce
 ntury health security threats.\n\n“With this investment in lipid product
 ion\, we are further expanding our leading position on the global market a
 nd specifically strengthening our Health Care business\,” said Evonik CE
 O Christian Kullmann. “It supports our strategic transformation into ‘
 Next Generation Evonik’\, contributing value-added solutions with superi
 or environmental and socio-economic profiles to our customers.”\n\nActiv
 e in more than 100 countries\, Evonik employs 33\,000 associates worldwide
 . Evonik’s Tippecanoe site in Lafayette is one of the world’s largest 
 sites for active pharmaceutical ingredients and Evonik's second-largest si
 te in the U.S. The company will begin hiring in Lafayette in 2024 for posi
 tions across operations\, quality assurance and control\, engineering and 
 supply chain. Interested applicants may apply online.\n\nBy expanding the 
 production of specialty lipids\, Evonik is strengthening the company’s n
 utrition and care division as it supports pharmaceutical companies worldwi
 de with comprehensive services for developing and manufacturing complex pa
 renteral and oral drug products.\n\n“As a strategic partner for pharma a
 nd biotech companies\, we are using the new facility to support our custom
 ers in developing nucleic acid-based drugs right up to commercialization. 
 These new therapies are the future\,” said Thomas Riermeier\, head of Ev
 onik's Health care business. “We are also evaluating further expansion o
 f our formulation services and scale-up capacity\, thereby consolidating o
 ur leading position as an end-to-end provider.” Pharmaceutical formulati
 on is a multi-step process of mixing the active drug with all other compon
 ents.\n \nThroughout the COVID-19 pandemic\, Evonik supplied lipids to the
  Pfizer/BioNTech COVID-19 vaccine and vaccination campaigns worldwide. The
  company has been supplying global pharmaceutical companies with the lipid
 s needed for use with mRNA active ingredients.\n\n“Evonik’s strategic 
 expansion at Tippecanoe is fantastic news for the entire Greater Lafayette
  region\,” said Scott Walker\, president and CEO of Greater Lafayette Co
 mmerce. “The town of Shadeland\, Lafayette\, West Lafayette\, Tippecanoe
  County\, the Purdue Research Foundation and Greater Lafayette Commerce al
 l supported this effort and not only look forward to the high-value jobs i
 t will create\, but also the important role the new Lipid Center of Excell
 ence will play in our nation’s vaccine preparedness.”\n\nPending appro
 val by the Indiana Economic Development Corporation (IEDC) board of direct
 ors\, the IEDC will commit an investment in Evonik Corporation of up to $2
 .1 million in the form of incentive-based tax credits and up to $250\,000 
 in conditional training grants. The IEDC will also offer up to $3 million 
 from the Hoosier Business Investment (HBI) tax credit program based on the
  company’s planned capital investment in Indiana. These tax credits are 
 performance-based\, meaning the company is eligible to claim incentives on
 ce Hoosiers are hired and trained. The Greater Lafayette Commerce and Duke
  Energy offered additional incentives.\n\nAbout Evonik\nEvonik is one of t
 he world leaders in specialty chemicals. The company is active in more tha
 n 100 countries around the world and generated sales of €15 billion and 
 an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik g
 oes far beyond chemistry to create innovative\, profitable\, and sustainab
 le solutions for customers. About 33\,000 employees work together for a co
 mmon purpose: We want to improve life today and tomorrow. To learn more\, 
 visit evonik.com \n\nAbout IEDC\nThe Indiana Economic Development Corporat
 ion (IEDC) is charged with growing the State economy\, driving economic de
 velopment\, helping businesses launch\, grow and locate in the state. Led 
 by Secretary of Commerce Brad Chambers\, @SecChambersIN\, and governed by 
 a 15-member board chaired by Governor Eric J. Holcomb\, @GovHolcomb\, the 
 IEDC manages many initiatives\, including performance-based tax credits\, 
 workforce training grants\, innovation and entrepreneurship resources\, pu
 blic infrastructure assistance\, and talent attraction and retention effor
 ts. For more information about the IEDC\, visit iedc.in.gov.\n\n- 30 -\n\n
  \nMedia Contacts: \nNorbert Kuls (Evonik) – 973 437-0542 norbert.kuls@e
 vonik.com\nMelissa Thomas (IEDC) – 317.750.4792 or mthomas@iedc.in.gov
LOCATION:
SUMMARY:[IEDC] German-based Life Sciences Company Evonik Invests $220M in T
 ippecanoe County Expansion
URL;VALUE=URI:https://events.in.gov/event/iedc_german-based_life_sciences_c
 ompany_evonik_invests_220m_in_tippecanoe_county_expansion
CATEGORIES:Press Releases
END:VEVENT
END:VCALENDAR